Form 4: TransMedics Group Executive Tamer Khayal Executes Stock Options and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold common stock on June 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On June 3, 2024, Tamer Khayal, the Chief Commercial Officer of TransMedics Group, Inc. (TMDX), executed stock options to acquire 2,960 shares of common stock at prices of $38.46, $66.10, and $13.28 per share.
  • Simultaneously, Khayal sold 3,010 shares of common stock at weighted average prices ranging from $129.92 to $135.97 per share.
  • These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
  • Following these transactions, Khayal directly owns 20,843 shares of TransMedics Group, Inc.
  • Khayal also holds options to purchase 13,125 shares exercisable until February 24, 2031, 13,766 shares exercisable until February 20, 2027 and 22,750 shares exercisable until February 22, 2026.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's prospects or strategy. It is common for executives to exercise stock options and sell shares for personal financial management.

Key Dates

DateDescription
09/06/2023Date of establishment of Rule 10b5-1 trading plan
02/24/2025Full vesting date for options to purchase 1,459 shares
02/22/2026Full vesting date for options to purchase 1,084 shares
02/20/2027Full vesting date for options to purchase 417 shares
02/20/2033Expiration date for options to purchase 417 shares
02/22/2032Expiration date for options to purchase 1,084 shares
02/24/2031Expiration date for options to purchase 1,459 shares
06/03/2024Date of stock option exercise and stock sales
06/05/2024Date of signature on the SEC Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.